RediMD, LLC – Trademark Portfolio

Entity Type: 16

RediMD, LLC holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 38 (Telecommunications) — 10 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include REDIMD, ASK AMY, FASTCHAT, and ADVANCING TELEMEDICINE. The owner is based in HOUSTON, TX.

9337 B Katy Freeway Suite 131

HOUSTON, TX 77024

14 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

RediMD, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

38
Telecommunications (10 filings)

Telecommunications

44
Medical Services (3 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does RediMD, LLC have?

RediMD, LLC has 14 U.S. trademarks filed with the USPTO. Of these, 4 registered, 10 abandoned.

What trademark classes does RediMD, LLC file in?

RediMD, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 38 (Telecommunications), Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 38 covers telecommunications.

What are RediMD, LLC's most well-known trademarks?

RediMD, LLC's registered trademark portfolio includes well-known marks such as REDIMD, ASK AMY, FASTCHAT, and ADVANCING TELEMEDICINE. These are among 4 currently registered trademarks in the portfolio.

What is RediMD, LLC's trademark registration success rate?

RediMD, LLC has a 29% trademark registration rate, with 4 out of 14 resolved applications resulting in successful registration. Currently, 0 applications are pending review.